Covid-19 vaccines have demonstrated the clinical potential of mRNA-Lipid Nanoparticle formulations. To enable the development of next-generation lipid-based drug delivery systems, expertise and manufacturing capabilities are critical.
Relying on more than 20 years experience in GMP lipid/LNP manufacturing, we aim at supporting pioneers in nucleic acid modalities to bring life changing medicines from preclinical to commercial manufacturing.
Speakers
Mahesh Karwa
MilliporeSigma
Associate Director, Process Development
Mahesh Karwa leads the process development group for MilliporeSigma at the Indianapolis site. With an 15 plus years of experience in the pharmaceutical industry, he has worked in analytical and process/product development teams previously. He joined the company in 2019, leading the analytical development group. He has contributed to the success of several client projects in the LNP & Liposomal fields for RNA delivery. Mahesh holds a Ph.D. in nanomaterials chemistry from New Jersey Institute of Technology.
Teresa Demuth
MilliporeSigma
Strategic Marketing Manager
Teresa Demuth holds a Ph.D. in biochemistry from the Swiss Federal Institute of Technology (ETH Zürich). As a product manager for synthetic lipids at MilliporeSigma, Teresa gained valuable experiences in the product and process development of synthetic lipids used in lipid-based RNA delivery and vaccines. In her current role, she is responsible for managing the company’s lipids portfolio and custom manufacturing businesses that support top industry players and young start-ups in the field of LNP drug delivery.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:1hr
Language:English
Session 1:presented March 30, 2023
To continue reading please sign in or create an account.
Don't Have An Account?